套细胞淋巴瘤(MCL)是晚期的B细胞非霍奇金淋巴瘤;它经常发生并影响淋巴结,脾,脾血液和骨髓.MCL骨髓受累(MCLBMI)与恶性肿瘤的同步发生极其罕见。据我们所知,先前尚未报道过同步性广泛期小细胞肺癌(ES-SCLC)和MCLBMI.在本研究中,据报道,1例59岁男性患者出现了1例罕见的ES-SCLC同步MCLBMI.病人接受了顺铂,依托泊苷,地塞米松和利妥昔单抗化疗治疗两种恶性肿瘤。随访计算机断层扫描显示左上叶肿块消退,常规血液检查表明血小板计数逐渐增加至正常水平。治疗后,患者获得了部分反应。本病例报告中的经验表明,同步SCLC和MCLBMI的治疗需要考虑各自患者的临床特征,两种恶性肿瘤治疗方案的生物学行为和累积毒性。本研究表明,血小板减少症不是化疗的禁忌症,从而为这类患者提供了新的治疗选择。
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma with an advanced stage; it occurs frequently and affects the lymph nodes, spleen, blood and bone marrow. The synchronous occurrence of MCL bone marrow involvement (MCLBMI) and malignant tumors is extremely rare. To the best of our knowledge, synchronous extensive-stage small cell lung cancer (ES-SCLC) and MCLBMI have not been previously reported. In the present study, a rare
case of ES-SCLC with synchronous MCLBMI is reported in a 59-year-old man. The patient received cisplatin, etoposide, dexamethasone and rituximab chemotherapy for the treatment of both malignancies. The follow-up computed tomography scan disclosed regression of the left upper lobe mass and the routine blood test indicated that the platelet count was gradually increasing to normal levels. Following therapy, the patient achieved a partial response. The experience in this
case report indicated that the treatment of synchronous SCLC and MCLBMI requires consideration of the respective patient clinical features, biological behavior and cumulative toxicity of the treatment regimens administered for both malignant tumors. The present study demonstrated that thrombocytopenia was not a chemotherapy contraindication, thus providing a new treatment option for this type of patient.